Citi lowered the firm’s price target on Surgery Partners to $43 from $47 and keeps a Buy rating on the shares post the Q3 repot. The analyst expected greater pricing/mix pull-through, but notes the company invested most of what otherwise would have been upside back into the business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGRY:
- Surgery Partners, Inc. Announces Third Quarter 2023 Results
- Surgery Partners sees 2023 revenue $2.75B, consensus $2.76B
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 16c
- SGRY Upcoming Earnings Report: What to Expect?
- Surgery Partners, Inc. Announces Third Quarter 2023 Earnings Release Date and Conference Call Details